These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23574312)

  • 1. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?
    Hilkens CM; Isaacs JD
    Clin Exp Immunol; 2013 May; 172(2):148-57. PubMed ID: 23574312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.
    Ma Y; Shi R; Li F; Chang H
    Cell Commun Signal; 2024 May; 22(1):262. PubMed ID: 38715122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.
    Satpute SR; Durai M; Moudgil KD
    Semin Arthritis Rheum; 2008 Dec; 38(3):195-207. PubMed ID: 18177689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.
    Giannoukakis N
    Front Immunol; 2023; 14():1212641. PubMed ID: 37388741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4
    Navarro-Barriuso J; Mansilla MJ; Quirant-Sánchez B; Teniente-Serra A; Ramo-Tello C; Martínez-Cáceres EM
    Front Immunol; 2020; 11():599623. PubMed ID: 33552054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal delivery of self-peptide and calcitriol as tolerogenic immunotherapy in rheumatoid arthritis: an exploration using sensory science.
    Hee JY; Cai B; Thomas R
    Immunol Cell Biol; 2024; 102(5):353-357. PubMed ID: 38216149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    Li V; Binder MD; Purcell AW; Kilpatrick TJ
    J Neuroimmunol; 2024 May; 390():578347. PubMed ID: 38663308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells: an immunotherapy coming of age.
    Stroncek DF; Marincola FM
    Immunotherapy; 2012 Oct; 4(10):973-4. PubMed ID: 23148746
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell-based therapies for the treatment of rheumatoid arthritis.
    Moghaddam MZ; Mousavi MJ; Ghotloo S
    Immun Inflamm Dis; 2023 Nov; 11(11):e1091. PubMed ID: 38018576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients.
    Benham H; Nel HJ; Law SC; Mehdi AM; Street S; Ramnoruth N; Pahau H; Lee BT; Ng J; Brunck ME; Hyde C; Trouw LA; Dudek NL; Purcell AW; O'Sullivan BJ; Connolly JE; Paul SK; Lê Cao KA; Thomas R
    Sci Transl Med; 2015 Jun; 7(290):290ra87. PubMed ID: 26041704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.
    Bell GM; Anderson AE; Diboll J; Reece R; Eltherington O; Harry RA; Fouweather T; MacDonald C; Chadwick T; McColl E; Dunn J; Dickinson AM; Hilkens CM; Isaacs JD
    Ann Rheum Dis; 2017 Jan; 76(1):227-234. PubMed ID: 27117700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis.
    Schinnerling K; Soto L; García-González P; Catalán D; Aguillón JC
    Autoimmun Rev; 2015 Jun; 14(6):517-27. PubMed ID: 25633325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in immune-based therapies for type 1 diabetes.
    von Herrath M; Peakman M; Roep B
    Clin Exp Immunol; 2013 May; 172(2):186-202. PubMed ID: 23574316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?
    Van Brussel I; Lee WP; Rombouts M; Nuyts AH; Heylen M; De Winter BY; Cools N; Schrijvers DM
    Autoimmun Rev; 2014 Feb; 13(2):138-50. PubMed ID: 24120737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune mechanisms in type 1 diabetes.
    Wållberg M; Cooke A
    Trends Immunol; 2013 Dec; 34(12):583-91. PubMed ID: 24054837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
    Makkouk A; Weiner GJ
    Cancer Res; 2015 Jan; 75(1):5-10. PubMed ID: 25524899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEC205+ Dendritic Cell-Targeted Tolerogenic Vaccination Promotes Immune Tolerance in Experimental Autoimmune Arthritis.
    Spiering R; Margry B; Keijzer C; Petzold C; Hoek A; Wagenaar-Hilbers J; van der Zee R; van Eden W; Kretschmer K; Broere F
    J Immunol; 2015 May; 194(10):4804-13. PubMed ID: 25862815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory dendritic cell therapy: from rodents to clinical application.
    Raïch-Regué D; Glancy M; Thomson AW
    Immunol Lett; 2014 Oct; 161(2):216-21. PubMed ID: 24316407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human dendritic cell subsets.
    Collin M; McGovern N; Haniffa M
    Immunology; 2013 Sep; 140(1):22-30. PubMed ID: 23621371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease.
    Phillips BE; Garciafigueroa Y; Trucco M; Giannoukakis N
    Front Immunol; 2017; 8():1279. PubMed ID: 29075262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.